Skip to main content
. 2017 Jun 20;16(2):1855–1863. doi: 10.3892/mmr.2017.6808

Figure 2.

Figure 2.

Reverse transcription-quantitative polymerase chain reaction analysis was used to validate the expression of miR-612 in the 70 samples. U6 was used as a control. The expression of miR-612 increased more than five-folds in tumors with LymphoMet compared to the tumors without. Data are presented as means ± standard deviation. *P<0.05 vs. normal group. miR, microRNA; LymphoMet, lymph node metastasis.